Pathogenic aspects of treatment of psoriatic patients

Cover Page

Cite item


The article describes high incidence and morbidity rate of psoriasis, substantial reduction in the life quality and psychosocial disadaptation of patients, and presents certain particular features of psoriasis pathogenesis taking into consideration the role of immune mechanisms and relation between the disease and other chronic processes in the organism, as a result of which psoriasis is considered to be a multimorbid condition. The multimorbidity of psoriasis is an important factor for selecting a therapy, especially for patients with severe forms of the disease.

About the authors

V. V. Chikin

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Russian Federation

L. F. Znamenskaya

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Russian Federation

A. A. Mineyeva

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Russian Federation


  1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009: 361 (5): 496 -509.
  2. Elder J.T. et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 2010: 130, 1213 -1226.
  3. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007 Jul 21; 370 (9583): 263 -71.
  4. L.F. Znamenskaya, L.Ye. Melekhina, Ye.V. Bogdanova, A.A. Mineye. Psoriasis incidence and prevalence in the Russian Federation. Vestn Dermatol Venerol 2012; (5): 20-29. [Знаменская Л.Ф., Мелехина Л.Е., Богданова Е.В., Минеева А.А. Заболеваемость и распространенность псориаза в Российской Федерации. Вестник дерматологии и венерологии 2012 (5): 20-29].
  5. Pujola R.M., Puiq L., Daudén E. Mental health selfassessment in patients with moderate to severe psoriasis: an observational, multicenter study of 1164 patients in Spain (the VACAP Study). Actas Dermosifiliogr. 2013 Dec; 104 (10): 897-903.
  6. Bouguéon K., Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135: Suppl 4: S254-8.
  7. Mudigonda P., Mudigonda T., Feneran A.N., Alamdari H.S., Sandoval L., Feldman S.R. (October 2012). Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J 18 (10): 1.
  8. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006; 444: 860-7S.
  9. Loo K.F., Yeung K.H., Ho K.M., Lo K.K. Cardiovascular comorbidities in psoriasis Hong Kong J. Dermatol. Venereol. (2010) 18, 72-81.
  10. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D. et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-6.
  11. El-Mongy S., Fathy H., Abdelaziz A., Omran E., George S., Neseem N., et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2009 Nov 2. [Epub ahead of print] online early assessed on 31st March 2010.
  12. Balci D.D., Balci A., Karazincir S., Ucar E., Iyigun U., Yalcin F. et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 1-6.
  13. Полотебнов А.Г. Дерматологические исследования. СПб. 1886-1887; Т. 1/2: С. 300 -350.
  14. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
  15. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X. et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-8.
  16. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 Suppl 2: 3-11.
  17. Papadavid E., Vlami K., Dalamaga M., Giatrakou S., Theodoropoulos K., Gyftopoulos S., Stavrianeas N., Papiris S., Rigopoulos D. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? J Eur Acad Dermatol Venereol 2013; 27: 820-826.
  18. Dalamaga M., Papadavid E., Vlami K. Unmasking the Janus face of the association between psoriasis, metabolic syndrome and obstructive sleep apnea. Sleep Breath 2013; 17: 449-450.
  19. Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011, Apr; 20 (4): 303-307.
  20. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
  21. Cohen A.D., Weitzman D., Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-6.
  22. Wakkee M., Thio H.B., Prens E.P., Sijbrands E.J., Neumann H.A. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9.
  23. Dreiher J., Weitzman D., Davidovici B., Shapiro J., Cohen A.D. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008; 88: 561-5.
  24. Mallbris L., Granath F., Hamsten A., Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-21.
  25. Love T.J., Qureshi A.A., Karlson E.W. et al. Prevalence of the metabolic syndrome in psoriasis: results from the national health and nutrition examination survey, 2003-2006. Arch Dermatol. 2011, Apr; 147 (4): 419- 424.
  26. Cheng J., Kuai D., Zhang L., Yang X., Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012; 304: 119-125.
  27. Akoglu H., Dede F., Akoglu G. et al. Membranoproliferative glomerulonephritis associated with psoriasis vulgaris. Ren Fail 2009, 31: 858-861.
  28. Abuabara K., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-92.
  29. Zadrazil J., Tichý T., Horák P., Nikorjaková I., Zima P., Krejcí K., Strébl P. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of 'psoriatic nephropathy'. J Nephrol. 2006 May-Jun; 19 (3): 382-6.
  30. Singh N.P., Prakash A., Kubba S., Ganguli A., Singh A.K., Sikdar S. et al. Psoriatic nephropathy- does an entity exist? Ren Fail 2005; 27: 123-7.
  31. Archier E., Devaux S., Castela E. et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 22-31.
  32. Naldi L., Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
  33. Menter A., Gottlieb A., Feldman S.R. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-50.
  34. Leonardi C.L., Powers J.L., Matheson R.T. et al.; for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.5.
  35. Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.6.
  36. Gordon K.B., Langley R.G., Leonardi C. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and openlabel extension study. J Am Acad Dermatol 2006; 55: 598-606.7.
  37. Krueger G.G., Langley R.G., Leonardi C. et al.; for the CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.8.
  38. Leonardi C.L., Kimball A.B., Papp K.A. et al.; for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
  39. Abuabara K., Wan J., Troxel A.B. et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 262-9.
  40. Gottlieb A., Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013 Oct; 5 (5): 277-285.
  41. Kurzeja M., Rudnicka L., Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011, Apr 1; 12 (2): 113-125.
  42. Laws P.M., Warren R.B. Ustekinumab for the treatment of psoriasis. Expert Rev Clin Immunol 2011, Mar; 7 (2): 155-64.
  43. Yeilding N., Szapary P., Brodmerkel C. et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci. 2011, Mar; 1222 (1): 30-39.
  44. Hsu L., Snodgrass B.T., Armstrong A.W. Anti-drug Antibodies in Psoriasis: A Systematic Review. Br J Dermatol 2013 Oct 1.
  45. Kimball AB1, Papp K.A., Wasfi Y. et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27 (12): 1535-45.
  46. Reich K., Langley R.G., Lebwohl M. et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011, Apr; 164 (4): 862-872.
  47. Langley R.G., Feldman S.R., Han C., Schenkel B., Szapary P., Hsu M.C., Ortonne J.P., Gordon K.B., Kimball A.B. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

Copyright (c) 2014 Chikin V.V., Znamenskaya L.F., Mineyeva A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies